Skip to main content

Advertisement

SpringerLink
Log in

Pitfalls and Opportunities in Measuring Patient Outcomes in Lupus

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Health outcomes and their measures used as end points in systemic lupus erythematosus (SLE) patient care and clinical trials have been varied and are still evolving. Although significant reductions in morbidity and mortality in SLE have been achieved, the medications approved for SLE have remained the same during the past 50 years. Despite the pressing need, aggressive advocacy in the community, and advances in drug development and testing in SLE, no medications have met US Food and Drug Administration guidelines for a new indication claim approval for SLE. This may be attributable to its multisystemic, remitting, and relapsing nature, and difficulty in identifying useful end points and appropriate tools to measure them. Thus, it is pivotal to identify and validate appropriate global, disease-specific, and perhaps organ-specific health outcomes for clinical research. This article reviews recent physician- and patient-generated health outcomes in SLE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. World Health Organization: Preamble to the Constitution of the World Health Organization as adopted by the International Health Conference. New York: World Health Organization; 1946.

    Google Scholar 

  2. Kozma CM, Reeder CE, Schulz RM: Economic, clinical, and humanistic outcomes: a planning model for pharmacoeconomic research. Clin Ther 1993, 15:1121–1132.

    CAS  PubMed  Google Scholar 

  3. Smolen JS, Strand V, Cardiel M, et al.: Randomized clinical trials and longitudinal observational studies in systemic lupus erythematosus: consensus on a preliminary core set of outcome domains. J Rheumatol 1999, 26:504–507.

    CAS  PubMed  Google Scholar 

  4. Uribe AG, Vilá LM, McGwin G Jr, et al.: The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2 K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol 2004, 31:1934–1940.

    PubMed  Google Scholar 

  5. Petri M, Kim MY, Kalunian KC, et al.: Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005, 353:2550–2558.

    Article  CAS  PubMed  Google Scholar 

  6. Yee CS, Farewell V, Isenberg DA, et al.: British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 2007, 56:4113–4119.

    Article  PubMed  Google Scholar 

  7. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria: The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum 2004, 50:3418–3426.

    Article  Google Scholar 

  8. Mosca M, Bencivelli W, Vitali C, et al.: The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosus. Lupus 2000, 9:445–450.

    Article  CAS  PubMed  Google Scholar 

  9. Krathen MS, Dunham J, Gaines E, et al.: The Cutaneous Lupus Erythematosus Disease Activity and Severity Index: expansion for rheumatology and dermatology. Arthritis Rheum 2008, 59:338–344.

    Article  CAS  PubMed  Google Scholar 

  10. Stoll T, Stucki G, Malik J, et al.: Association of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index with measures of disease activity and health status in patients with systemic lupus erythematosus. J Rheumatol 1997, 24:309–313.

    CAS  PubMed  Google Scholar 

  11. Petri M, Buyon J, Kalunian KC, et al.: Revision of the SELENA Flare Index [abstract]. Arthritis Rheum 2009, 60(10s).

  12. Furie RA, Petri MA, Wallace DJ, et al.: Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009, 61:1143–1151.

    Article  CAS  PubMed  Google Scholar 

  13. Abrahamowicz M, Fortin PR, du Berger R, et al.: The relationship between disease activity and expert physician’s decision to start major treatment in active systemic lupus erythematosus: a decision aid for development of entry criteria for clinical trials. J Rheumatol 1998, 25:277–284.

    CAS  PubMed  Google Scholar 

  14. Alarcón GS, Roseman JM, McGwin G Jr, et al.: Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage. Rheumatology (Oxford) 2004, 43:202–205.

    Article  Google Scholar 

  15. Danila MI, Pons-Estel GJ, Zhang J, et al.: Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. Rheumatology (Oxford) 2009, 48:542–545.

    Article  Google Scholar 

  16. • Bertsias GK, Ioannidis JP, Boletis J, et al.: EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints. Ann Rheum Dis 2009, 68:477–483. This article summarizes the category of evidence and strengths of statements used for clinical and patient-reported outcomes in SLE.

    Article  CAS  PubMed  Google Scholar 

  17. Petri M, Kasitanon N, Singh S, et al.: Systemic lupus international collaborating clinics renal activity/response exercise: comparison of agreement in rating renal response. Arthritis Rheum 2008, 58:1789–1795.

    Article  PubMed  Google Scholar 

  18. Karlson EW, Daltroy LH, Rivest C, et al.: Validation of a Systemic Lupus Activity Questionnaire (SLAQ) for population studies. Lupus 2003, 12:280–286.

    Article  CAS  PubMed  Google Scholar 

  19. Pons-Estel BA, Sánchez-Guerrero J, Romero-Díaz J, et al.: Validation of the Spanish, Portuguese and French versions of the Lupus Damage Index questionnaire: data from North and South America, Spain and Portugal. Lupus 2009, 18:1033–1052.

    Article  CAS  PubMed  Google Scholar 

  20. Curry SL, Levine SB, Corty E, et al.: The impact of systemic lupus erythematosus on women’s sexual functioning. J Rheumatol 1994, 21:2254–2260.

    CAS  PubMed  Google Scholar 

  21. Jolly M, Pickard AS, Mikolaitis R, et al.: Disease activity, body image and health status in lupus. Arthritis Rheum 2007, 56:S454.

    Google Scholar 

  22. Law G, Lalani S, Pope J, et al.: The relationship between health care access and disease activity and damage in a multiethnic cohort of systemic lupus erythematosus patients: the 1000 Canadian Faces of Lupus Study. Arthritis Rheum 2008, 58:S881.

    Google Scholar 

  23. Jolly M, Pickard AS, Wilke CT, et al.: Satisfaction with care and health status in lupus. Arthritis Rheum 2007, 56:S114.

    Google Scholar 

  24. Alarcón GS, McGwin G Jr, Brooks K, et al.: Systemic lupus erythematosus in three ethnic groups. XI. Sources of discrepancy in perception of disease activity: a comparison of physician and patient visual analog scale scores. Arthritis Rheum 2002, 47:408–413.

    Article  PubMed  Google Scholar 

  25. Leong KP, Chong EY, Kong KO, et al.: Discordant assessment of lupus activity between patients and their physicians: the Singapore experience. Lupus 2010, 19:100–106.

    Article  CAS  PubMed  Google Scholar 

  26. Jolly M, Utset TO: Can disease specific measures for systemic lupus erythematosus predict patients health related quality of life? Lupus 2004, 13:924–926.

    Article  CAS  PubMed  Google Scholar 

  27. Aggarwal R, Wilke CT, Pickard AS, et al.: Psychometric properties of the EuroQOL-5D and Short Form-6D in patients with systemic lupus erythematosus. J Rheumatol 2009, 36:1209–1216.

    Article  PubMed  Google Scholar 

  28. Alarcón GS, McGwin G Jr, Uribe A, et al.: Systemic lupus erythematosus in a multiethnic lupus cohort (LUMINA). XVII. Predictors of self-reported health-related quality of life early in the disease course. Arthritis Rheum 2004, 51:465–474.

    Article  PubMed  Google Scholar 

  29. Ginzler EM, Wofsy D, Isenberg D, et al.: Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum 2010, 62:211–221.

    Article  PubMed  Google Scholar 

  30. Lu F, Tu Y, Peng X, et al.: A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis. Lupus 2008, 17:622–629.

    Article  CAS  Google Scholar 

  31. Merrill JT, Neuwelt CM, Wallace DJ, et al.: Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010, 62:222–233.

    Article  PubMed  Google Scholar 

  32. • Kuriya B, Gladman DD, Ibañez D, Urowitz MB: Quality of life over time in patients with systemic lupus erythematosus. Arthritis Rheum 2008, 59:181–185. The study evaluates the changes in SF-36 over time in an SLE cohort. It also tabulates the baseline demographic and clinical predictors of change in SF-36.

    Article  PubMed  Google Scholar 

  33. Tucker LB, Uribe AG, Fernández M, et al.: Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus 2008, 17:314–322.

    Article  CAS  PubMed  Google Scholar 

  34. Zhu TY, Tam LS, Lee VW, et al.: Relationship between flare and health-related quality of life in patients with systemic lupus erythematosus. J Rheumatol 2010, 37:568–573.

    Article  PubMed  Google Scholar 

  35. Appenzeller S, Clarke AE, Panopalis P, et al.: The relationship between renal activity and quality of life in systemic lupus erythematosus. J Rheumatol 2009, 36:947–952.

    Article  PubMed  Google Scholar 

  36. Boström C, Dupré B, Tengvar P, et al.: Aerobic capacity correlates to self-assessed physical function but not to overall disease activity or organ damage in women with systemic lupus erythematosus with low-to-moderate disease activity and organ damage. Lupus 2008, 17:100–104.

    Article  PubMed  Google Scholar 

  37. Jolly M, Block JA, Rodby RL: Effect of lupus on sexual health of women. Arthritis Rheum 2008, 56:S589.

    Google Scholar 

  38. Curry SL, Levine SB, Jones PK, Kurit DM: Medical and psychosocial predictors of sexual outcome among women with systemic lupus erythematosus. Arthritis Care Res 1993, 6:23–30.

    Article  CAS  PubMed  Google Scholar 

  39. Stein H, Walters K, Dillon A, Schulzer M: Systemic lupus erythematosus—a medical and social profile. J Rheumatol 1986, 13:570–576.

    CAS  PubMed  Google Scholar 

  40. Bachen EA, Chesney MA, Criswell LA: Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus. Arthritis Rheum 2009, 61:822–829.

    Article  PubMed  Google Scholar 

  41. Huang HC, Chou CT, Lin KC, Chao YF: The relationships between disability level, health-promoting lifestyle, and quality of life in outpatients with systemic lupus erythematosus. J Nurs Res 2007, 15:21–32.

    PubMed  Google Scholar 

  42. Bultink IE, Turkstra F, Dijkmans BA, Voskuyl AE: High prevalence of unemployment in patients with systemic lupus erythematosus: association with organ damage and health-related quality of life. J Rheumatol 2008, 35:1053–1057.

    PubMed  Google Scholar 

  43. Al Dhanhani AM, Gignac MA, Su J, Fortin PR: Work disability in systemic lupus erythematosus. Arthritis Rheum 2009, 61:378–385.

    Article  PubMed  Google Scholar 

  44. Danoff-Burg S, Friedberg F: Unmet needs of patients with systemic lupus erythematosus. Behav Med 2009, 35:5–13.

    Article  PubMed  Google Scholar 

  45. Trupin L, Tonner MC, Yazdany J, et al.: The role of neighborhood and individual socioeconomic status in outcomes of systemic lupus erythematosus. J Rheumatol 2008, 35:1782–1788.

    PubMed  Google Scholar 

  46. Friedman AW, Alarcón GS, McGwin G Jr, et al.: Systemic lupus erythematosus in three ethnic groups. IV. Factors associated with self-reported functional outcome in a large cohort study. LUMINA Study Group. Lupus in Minority Populations, Nature Versus Nurture. Arthritis Care Res 1999, 12:256–266.

    Article  CAS  PubMed  Google Scholar 

  47. Cervera J, Ishimori ML, Cooray D, et al.: Predictors of SF36 scores in a new lupus cohort in southern California. Arthritis Rheum 2009, 60:S515.

    Google Scholar 

  48. Jump RL, Robinson ME, Armstrong AE, et al.: Fatigue in systemic lupus erythematosus: contributions of disease activity, pain, depression, and perceived social support. J Rheumatol 2005, 32:1699–1705.

    PubMed  Google Scholar 

  49. Burgos PI, Alarcón GS, McGwin G Jr, et al.: Disease activity and damage are not associated with increased levels of fatigue in systemic lupus erythematosus patients from a multiethnic cohort: LXVII. Arthritis Rheum 2009, 61:1179–1186.

    Article  PubMed  Google Scholar 

  50. Monaghan SM, Sharpe L, Denton F, et al.: Relationship between appearance and psychological distress in rheumatic diseases. Arthritis Rheum 2007, 57:303–309.

    Article  PubMed  Google Scholar 

  51. Moorthy LN, Peterson MG, Hassett A, et al.: Impact of lupus on school attendance and performance. Lupus 2010 Jan 11 (Epub ahead of print).

  52. Tonner MC, Trupin L, Yelin E, et al.: Assessing the quality of patient-physician communication in a large cohort of subjects with SLE. Arthritis Rheum 2008, 58:S881.

    Google Scholar 

  53. Da Costa D, Clarke AE, Dobkin PL, et al.: The relationship between health status, social support and satisfaction with medical care among patients with systemic lupus erythematosus. Int J Qual Health Care 1999, 11:201–207.

    Article  PubMed  Google Scholar 

  54. Wolfe F, Michaud K: Measuring the burden of out of pocket expenses in patients with rheumatic disease: usefulness of the out of pocket burden (OPB) scale. Arthritis Rheum 2008, 58:S206.

    Article  Google Scholar 

  55. Chambers SA, Raine R, Rahman A, Isenberg D: Why do patients with systemic lupus erythematosus take or fail to take their prescribed medications? A qualitative study in a UK cohort. Rheumatology (Oxford) 2009, 48:266–271.

    Article  CAS  Google Scholar 

  56. Pineau C, Da Costa D, Bernatsky S, et al.: Determinants of adherence to therapy in systemic lupus erythematosus. Arthritis Rheum 2008, 58:S809.

    Google Scholar 

  57. Julian LJ, Yelin E, Yazdany J, et al.: Depression, medication adherence, and service utilization in systemic lupus erythematosus. Arthritis Rheum 2009, 61:240–246.

    Article  PubMed  Google Scholar 

  58. Jolly M: How does quality of life of patients with systemic lupus erythematosus compare with that of other common chronic illnesses? J Rheumatol 2005, 32:1706–1708.

    PubMed  Google Scholar 

  59. Campbell R Jr, Cooper GS, Gilkeson GS: Two aspects of the clinical and humanistic burden of systemic lupus erythematosus: mortality risk and quality of life early in the course of the disease. Arthritis Rheum 2008, 59:458–464.

    Article  PubMed  Google Scholar 

  60. Brunner HI, Higgins GC, Wiers K, et al.: Health-related quality of life and its relationship to patient disease course in childhood-onset systemic lupus erythematosus. J Rheumatol 2009, 36:1536–1545.

    Article  PubMed  Google Scholar 

  61. Wolfe F, Michaud K, Li T, Katz RS: EQ-5D and SF-36 quality of life measures in systemic lupus erythematosus: comparisons with rheumatoid arthritis, non inflammatory rheumatic disorders, and fibromyalgia. J Rheumatol 2010, 37:296–304.

    Article  PubMed  Google Scholar 

  62. Hersh AO, von Scheven E, Yazdany J, et al.: Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus. Arthritis Rheum 2009, 61:13–20.

    Article  PubMed  Google Scholar 

  63. Uribe AG, Romero-Díaz J, Apte M, et al.: Impact of immigration on the clinical expression of systemic lupus erythematosus: a comparative study of Hispanic patients residing in the USA and Mexico. Rheumatology 2009, 48:1392–1397.

    Article  PubMed  Google Scholar 

  64. Tam LS, Wong A, Mok VC, et al.: The relationship between neuropsychiatric, clinical, and laboratory variables and quality of life of Chinese patients with systemic lupus erythematosus. J Rheumatol 2008, 35:1038–1045.

    PubMed  Google Scholar 

  65. Jolly M, Patel R, Aggarwal R, et al.: Is cigarette smoking and independent correlate of health related quality of life in patients with systemic lupus erythematosus? Arthritis Rheum 2010, 60:S108.

    Google Scholar 

  66. Moghadam-Kia S, Chilek K, Gaines E, et al.: Cross-sectional analysis of a collaborative Web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients. Arch Dermatol 2009, 145:255–260.

    Article  PubMed  Google Scholar 

  67. Scalzi LV, Ballou SP, Park JY, et al.: Cardiovascular disease risk awareness in systemic lupus erythematosus patients. Arthritis Rheum 2008, 58:1458–1464.

    Article  PubMed  Google Scholar 

  68. Greco CM, Kao AH, Sattar A, et al.: Association between depression and coronary artery calcification in women with systemic lupus erythematosus. Rheumatology (Oxford) 2009, 48:576–581.

    Article  Google Scholar 

  69. Aghdassi E, Morrison S, Landolt-Marticorena C, et al.: The use of micronutrient supplements is not associated with better quality of life and disease activity in Canadian patients with systemic lupus erythematosus. J Rheumatol 2010, 37:87–90.

    Article  PubMed  Google Scholar 

  70. Jolly M, Sandler DS, Sequeira W, Block JA: Hydroxy-chloroquine use and disease specific health related quality of life in systemic lupus erythematosus. Arthritis Rheum 2010, 60:S108.

    Google Scholar 

  71. Alvarez-Nemegyei J, Bautista-Botello A, Dávila-Velázquez J: Association of complementary or alternative medicine use with quality of life, functional status or cumulated damage in chronic rheumatic diseases. Clin Rheumatol 2009, 28:547–551.

    Article  PubMed  Google Scholar 

  72. Campbell R, Cooper GS, Gilkeson GS: The economic burden of systemic lupus erythematosus among patients of the Carolina Lupus Study early in the course of disease. Arthritis Rheum 2008, 58:S416.

    Google Scholar 

  73. Baker K, Pope J, Fortin P, et al.: Work disability in systemic lupus erythematosus is prevalent and associated with socio-demographic and disease related factors. Lupus 2009, 18:1281–1288.

    Article  CAS  PubMed  Google Scholar 

  74. Clarke AE, Panopalis P, Petri M, et al.: SLE patients with renal damage incur higher health care costs. Rheumatology (Oxford) 2008, 47:329–333.

    Article  CAS  Google Scholar 

  75. Panopalis P, Petri M, Manzi S, et al.: The systemic lupus erythematosus Tri-Nation Study: cumulative indirect costs. Arthritis Rheum 2007, 57:64–70.

    Article  PubMed  Google Scholar 

  76. Furie R, Stohl W, Ginzler EM, et al.: Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008, 10:R109.

    Article  PubMed  Google Scholar 

  77. Urowitz MB, Gladman DD, Ibanez D, et al.: Disease outcomes in the first 4 years of SLE: results from the SLICC inception cohort. Arthritis Rheum 2007, 56:S454.

    Google Scholar 

  78. Hanly JG, Su L, Farewell V, et al.: Prospective study of neuro-psychiatric events in systemic lupus erythematosus. J Rheumatol 2009, 36:1449–1459.

    Article  PubMed  Google Scholar 

  79. Hanly JG, Urowitz MB, Su L, et al.: Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2010, 69:529–535.

    Article  CAS  PubMed  Google Scholar 

  80. Kellner E, Lee P, Li Y, et al.: The interferon signature is not associated with depression and fatigue in systemic lupus erythematosus. Arthritis Rheum 2009, 60:S420.

    Google Scholar 

  81. Nietert PJ, Brown R, Shaftman SR, et al.: A randomized clinical trial to enhance adjustment and disease adaptation among adolescent females with lupus. Arthritis Rheum 2008, 58:S161.

    Google Scholar 

  82. Navarrete-Navarrete N, Peralta-Ramírez MI, Sabio-Sánchez JM, et al.: Efficacy of cognitive behavioural therapy for the treatment of chronic stress in patients with lupus erythematosus: a randomized controlled trial. Psychother Psychosom 2010, 79:107–115.

    Article  CAS  PubMed  Google Scholar 

  83. Dussán KB, Magder L, Brodsky RA, et al.: High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures. Lupus 2008, 17:1079–1085.

    Article  PubMed  Google Scholar 

  84. Gordon C, Wallace DJ, Shinada S, et al.: Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus. Rheumatology (Oxford) 2008, 47:334–338.

    Article  CAS  Google Scholar 

  85. Fortin PR, Abrahamowicz M, Ferland D, et al.: Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2008, 59:1796–1804.

    Article  CAS  PubMed  Google Scholar 

  86. Wallace DJ, Stohl W, Furie RA, et al.: A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009, 61:1168–1178.

    Article  CAS  PubMed  Google Scholar 

  87. Henrikson EW, Jonsdottir T, Gunnarsson I, et al. : Reduced fatigue and improved self perceived social function in patients with severe SLE treated with rituximab. Arthritis Rheum 2007, 56:S826.

    Google Scholar 

  88. Strand V, Gordon C, Kalunian K, et al.: Meaningful improvements in health related quality of life with epratuzumab in patients with SLE with high disease activity. Arthritis Rheum 2008, 58:S570.

    Google Scholar 

  89. Cardiel MH, Tumlin JA, Furie RA, et al.: Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum 2008, 58:2470–2480.

    Article  CAS  PubMed  Google Scholar 

  90. Ward MM, Sundaramurthy S, Lotstein D, et al.: Participatory patient-physician communication and morbidity in patients with systemic lupus erythematosus. Arthritis Rheum 2003, 49:810–818.

    Article  PubMed  Google Scholar 

  91. Sanchez ML, McGwin G Jr, Duran S, et al.: Factors predictive of overall health over the course of the disease in patients with systemic lupus erythematosus from the LUMINA cohort (LXII): use of the SF-6D. Clin Exp Rheumatol 2009, 27:67–71.

    CAS  PubMed  Google Scholar 

  92. Fernández M, Alarcón GS, McGwin G Jr, et al.: Using the Short Form 6D, as an overall measure of health, to predict damage accrual and mortality in patients with systemic lupus erythematosus: XLVII, results from a multiethnic US cohort. Arthritis Rheum 2007, 57:986–992.

    Article  PubMed  Google Scholar 

  93. Mok CC, Ho LY, Cheung MY, et al.: Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study. Scand J Rheumatol 2009, 38:121–127.

    Article  CAS  PubMed  Google Scholar 

  94. Wolfe F, Michaud K, Li T, et al.: Assessment of lupus mortality in patient based community data bank. Arthritis Rheum 2009, 60:S352.

    Google Scholar 

Download references

Disclosure

Meenakshi Jolly has received compensation from MedImmune for allowing use of a copyrighted survey tool for its study and has received a research grant from the Lupus Foundation of America.

Author information

Authors and Affiliations

  1. Departments of Medicine and Behavioral Medicine, Rush Lupus Clinic, Rush University Medical Center, 1725 West Harrison Street, Suite 1017, Chicago, IL, 60612, USA

    Meenakshi Jolly

Authors
  1. Meenakshi Jolly
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Meenakshi Jolly.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jolly, M. Pitfalls and Opportunities in Measuring Patient Outcomes in Lupus. Curr Rheumatol Rep 12, 229–236 (2010). https://doi.org/10.1007/s11926-010-0105-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-010-0105-2

Keywords

Search

Navigation